



PRESS RELEASE

## ***MolMed S.p.A. Corporate bylaw update publication***

Milan (Italy), March 31<sup>st</sup> 2020 – MolMed S.p.A. (MLMD.MI) informs that as of today the Corporate bylaws, filed with the Companies' Register of Milan on March 20<sup>th</sup> 2020 and therein registered on March, 23<sup>rd</sup> 2020, updated at the article 5 – “Capitale Sociale e azioni” (Shareholders Capital and shares), is available, in accordance with the regulations in force, on the authorized storage device 1Info (<https://www.1info.it>) with changes highlighted in appendix. The Corporate bylaws is also available (in Italian) on the Company's website [www.molmed.com](http://www.molmed.com) in the section “Investors/Corporate Governance/Corporate Bylaws”.

### ***About MolMed***

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit [www.molmed.com](http://www.molmed.com).

### ***For further information:***

#### **Molmed S.p.A.**

**Ilaria Candotti**  
*Investor Relations & Communication Manager*  
MolMed S.p.A.  
+39 02 21277.205  
[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Tommasina Cazzato**  
*Press Office*  
Community Group  
+39 345 7357751  
[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)